Evidence map›Paper›PMID 40969221›Full record

ReviewJournal of Alzheimer's disease reports

Brexpiprazole: Pioneering medication for managing agitation in Alzheimer's disease.

Ayesha Shaukat, Rumaisa Riaz, Nawal Khaliq, Zubayer Shams, Aymar Akilimali

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ayesha ShaukatDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.ORCID https://orcid.org/0009-0006-1541-3037
Rumaisa RiazDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.ORCID https://orcid.org/0000-0002-2277-0183
Nawal KhaliqDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.ORCID https://orcid.org/0009-0000-6853-8024
Zubayer ShamsBrunel medical school, Brunel University, London, UK.ORCID https://orcid.org/0009-0008-3900-4419
Aymar AkilimaliDepartment of research, Medical Research Circle (MedReC), Goma, Democratic Republic of the Congo.ORCID https://orcid.org/0000-0001-9393-1215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease poses intricate challenges, affecting cognition and behavior, notably marked by agitation. The FDA's approval of brexpiprazole, an atypical antipsychotic, stands as a milestone, representing the first treatment for Alzheimer's-related agitation. brexpiprazole's modulation of serotonin-dopamine activity has proven effective in clinical trials, reducing agitation as measured by CMAI scores. Gradual dosage escalation is recommended, with potential side effects including nasopharyngitis, urinary tract infections, dizziness, somnolence, headache, and insomnia. Also useful for schizophrenia and treatment-resistant depression, providing ongoing treatment and potential well-being enhancement by managing agitation and other symptoms.

Indexed as

agitationAlzheimer's diseasebrexpiprazolefood and drug administrationserotonin-dopamine activity modulator

Identifiers

PMID40969221
PMCPMC12441263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.